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Abstract 
We report the detection of extensively drug resistant 
strains of Mycobacterium tuberculosis in Kerala, India. 
Earlier we had reported that 22 of 206 local isolates were 
multidrug resistant. Now, we tested the same isolates for 
their resistance to ofloxacin and amikacin. Six among the 
MDR isolates showed resistance to both drugs and 
therefore fall under XDR category.  
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Introduction 
India harbored the largest number of tuberculosis (TB) cases in 
2008[1]. TB control programs have been badly hit with the 
emergence of drug resistant strains of M. tuberculosis. Multidrug 
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resistant (MDR) -TB occurs when the bacteria are resistant to at 
least isoniazid and rifampicin, the two most potent first-line anti-
TB drugs. MDR-TB is treated using second-line drugs which 
include two major classes, fluoroquinolones and aminoglycosides. 
TB caused by M. tuberculosis strains resistant to any 
fluoroquinolone, and at least one of the three injectable second-line 
drugs (capreomycin, kanamycin, and amikacin), in addition to 
being MDR, is called extensively drug resistant tuberculosis (XDR-
TB) [2]. Ten percent of MDR-TB tested worldwide was found to be 
XDR-TB [3]. The combination of HIV/AIDS and XDR-TB could 
become a great survival challenge for humanity.  
To date there are only few reports on XDR-TB from India. The first 
report on the prevalence of XDR-TB in India was in 2007 from a 
retrospective study in which they showed occurrence of 7.4% XDR-
TB cases among MDR-TB patients in Lucknow [4], and 8% from a 
tertiary care center in Mumbai [5].  Recently a low prevalence 
(2.4%) of XDR cases was reported in another hospital-based study 
from New Delhi [6]. While Gujarat had 3.2% cases [7], the scenario 
is alarming in the eastern states of India with 22.2% XDR cases [8].  
Materials and methods 
In an earlier study, we had analyzed the resistance profile of M. 
tuberculosis isolated from TB patients in Kerala. In this retrospective 
analysis, we studied 206 isolates of M. tuberculosis cultured from 
the sputum samples of tuberculosis patients attending TB clinics 
from different parts of Kerala. Of them, 92 were from new cases 
and 104 cases were from re-treatment cases.  Treatment status of 10 
patients was unknown. We observed a prevalence of MDR at 10.7% 
(5.4% in new cases and 16.4% in re-treatment cases) [9]. 
Subsequently, we analyzed the same isolates for their resistance to 
second-line drugs also. The susceptibility of these isolates to two 
second-line drugs, ofloxacin and amikacin was tested at 0.5, 1.0 and 
2.0 µg/ml by resazurin microtire assay (REMA) as described by 
Martin et al. [10]5 This study was approved by the Institutional 
Biosafety and Ethics Committees. As this was a retrospective study, 
informed consent from the patients was not required.  




Among the 206 isolates analysed for their DST against second line 
drugs, 19 were resistant to ofloxacin and 13 were resistant to 
amikacin (Fig 1). All the amikacin resistant ones were resistant to 
oflaxacin also. Of these 13 amikacin and ofloxacin resistant isolates, 
six were MDR and hence met the definition of being XDR. 
Representative strains from these clinical isolates belonging to each 
resistance category i.e. pansusceptible, MDR and XDR along with 
M. tuberculosis H37Rv were analyzed by automated BACTEC MGIT 
960 TB system (Becton Dickinson) for validation of the drug 
susceptibility testing protocol and we observed 100% correlation 
between the results of  REMA and MGIT.  
Discussion 
The clinical history of these six XDR patients revealed that all were 
re-treatment cases. Thus in this study, XDR TB was found only in 
re-treatment cases (5.76%, 6/104). XDR among MDR cases is 27% 
(6/22). As per the details provided by the physicians, two of these 
patients were already under treatment with second-line drugs at 
the time of sputum collection while the others were not. Age or sex 
of the patients did not show any obvious propensity to XDR TB. 
Among the isolates, 162 were from males and 44 from females and 
the age varied widely between 12-85 years.  However XDR-TB was 
found to be in the age group of 20-58 years (5 males: 1 female). 
Since the drug sensitivity analysis was done on samples collected 
from public sector hospitals and TB clinics, blood samples were not 
collected from the patients to determine their HIV status. 
Moreover, because of the social stigma and discrimination that may 
ensue, the physicians do not recommend it either. Therefore, the 
correlation between TB infection and HIV status of the patients 
could not be included in this study.  
World Health Organization (WHO) considers XDR-TB a serious 
emerging threat to global public health, especially in countries with 
high prevalence of HIV. Even though HIV prevalence in Kerala is 
low [11], tuberculosis alone can be a health hazard because of the 
high population density. The observation calls for immediate 
measures to be taken to control and contain the spread of drug 




resistant strains of M. tuberculosis. Fortunately DOTS plus treatment 
has been implemented recently in Kerala [11]  and we hope it will 
help contain the spread of the disease in this state effectively. 
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Fig 1. Extensive Drug resistance (XDR) in M. tuberculosis isolated from TB patients in Kerala. MDR 
- Multidrug resistant isolates, Oflox - isolates resistant to Ofloxacin, Amik- isolates resistant to 
Amikacin. 
 
 
 
 
